Compare NetApp Inc. (NTAP) vs TG Therapeutics Inc (TGTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
NetApp Inc. vs TG Therapeutics Inc — how do they compare? NetApp Inc. trades at $236.56 (market cap $45.38B), while TG Therapeutics Inc trades at $54.88 (market cap $8.16B). The key difference: NetApp Inc. is far larger — about 5.6× TG Therapeutics Inc's market cap, and NetApp Inc. pays a 0.9% dividend while TG Therapeutics Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold NetApp Inc. for 56 Days and TG Therapeutics Inc for 16 Days on average.
| NTAP | TGTX | |
|---|---|---|
Market Cap | $45.38B | $8.16B |
Volume | 2,264,311 | 1,735,121 |
Sector | Technology | Health |
52-Week High | $235.84 | $59.06 |
52-Week Low | $94.11 | $26.94 |
Typical Hold Time | 56 Days | 16 Days |
Enterprise Value | $44.34B | $8.37B |
Dividend Yield | 0.9% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
NTAP trades at $235.68, near its 52-week high, with a bullish technical outlook supported by moving averages and strong quarterly earnings beats. The company reported robust profitability with a net income margin of 19.19% and ROE of 114.82% for 2025. Recent news highlights strategic AI partnerships with Oracle and Supermicro, enhancing its data infrastructure offerings and market positioning.
The stock presents growth potential driven by AI-driven demand and expanding partnerships, but faces risks from high valuation multiples and competitive pressures. Analyst consensus is mixed with a hold rating bias, though price targets suggest moderate downside from current levels. Investors should weigh strong fundamentals against valuation concerns and market volatility.
TG Therapeutics (TGTX) trades at $54.80, up 3.49% today, but faces a bearish technical signal with recent earnings misses. Revenue growth is strong, with 2026 guidance raised to $950M for BRIUMVI, and net income margins exceed 55%. However, cash flow was negative in 2025, and a shareholder litigation investigation adds near-term uncertainty.
The outlook is mixed: analyst consensus is bullish with an $80.50 price target, but execution risks and earnings volatility persist. Upside hinges on BRIUMVI market share gains and subcutaneous formulation progress, while legal and competitive pressures pose threats to shareholder value.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About NetApp Inc.
NetApp is a leading provider of enterprise data management and storage solutions. The company's three operating business units are products, software maintenance, and hardware maintenance. NetApp transitioned from a data center storage firm to a company with software data management solutions for multicloud environments. The California-headquartered company sells globally and has approximately 10,000 employees.
Read more on NTAP →About TG Therapeutics Inc
TG Therapeutics is a fully integrated biopharmaceutical company focused on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases. Its cornerstone product, BRIUMVI (ublituximab-xiiy), is a glycoengineered monoclonal antibody approved for relapsing forms of multiple sclerosis. The company is currently executing a 'pipeline-in-a-product' strategy, expanding BRIUMVI into new delivery methods and indications while advancing a broader portfolio of autoimmune and oncology candidates.
Read more on TGTX →
